IL259508A - 1, 3, 4-thiadiazole compounds and their use for cancer treatment - Google Patents

1, 3, 4-thiadiazole compounds and their use for cancer treatment

Info

Publication number
IL259508A
IL259508A IL259508A IL25950818A IL259508A IL 259508 A IL259508 A IL 259508A IL 259508 A IL259508 A IL 259508A IL 25950818 A IL25950818 A IL 25950818A IL 259508 A IL259508 A IL 259508A
Authority
IL
Israel
Prior art keywords
treating cancer
thiadiazole compounds
thiadiazole
compounds
cancer
Prior art date
Application number
IL259508A
Other languages
English (en)
Hebrew (he)
Original Assignee
Astrazeneca Ab
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Cancer Research Tech Ltd filed Critical Astrazeneca Ab
Publication of IL259508A publication Critical patent/IL259508A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
IL259508A 2015-11-30 2018-05-22 1, 3, 4-thiadiazole compounds and their use for cancer treatment IL259508A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562260784P 2015-11-30 2015-11-30
PCT/EP2016/079253 WO2017093301A1 (en) 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
IL259508A true IL259508A (en) 2018-07-31

Family

ID=57460503

Family Applications (1)

Application Number Title Priority Date Filing Date
IL259508A IL259508A (en) 2015-11-30 2018-05-22 1, 3, 4-thiadiazole compounds and their use for cancer treatment

Country Status (28)

Country Link
US (1) US10040789B2 (enExample)
EP (1) EP3383872B1 (enExample)
JP (1) JP6821680B2 (enExample)
KR (1) KR20180083411A (enExample)
CN (1) CN108349965B (enExample)
AR (1) AR106875A1 (enExample)
AU (1) AU2016361834B2 (enExample)
BR (1) BR112018008330B1 (enExample)
CA (1) CA3005517C (enExample)
CL (1) CL2018001409A1 (enExample)
CO (1) CO2018006930A2 (enExample)
DK (1) DK3383872T3 (enExample)
DO (1) DOP2018000135A (enExample)
EA (1) EA035519B9 (enExample)
ES (1) ES2796562T3 (enExample)
IL (1) IL259508A (enExample)
MX (1) MX2018006483A (enExample)
MY (1) MY195680A (enExample)
NI (1) NI201800063A (enExample)
NZ (1) NZ743699A (enExample)
PE (1) PE20181522A1 (enExample)
PH (1) PH12018501133A1 (enExample)
SG (1) SG11201803808VA (enExample)
SV (1) SV2018005700A (enExample)
TN (1) TN2018000118A1 (enExample)
TW (1) TW201731511A (enExample)
WO (1) WO2017093301A1 (enExample)
ZA (1) ZA201804361B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US9938265B2 (en) 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
ES2939506T3 (es) 2018-10-16 2023-04-24 Medshine Discovery Inc Derivado de tiadiazol y usos del mismo como inhibidor de GLS1 para el tratamiento de cáncer
CN114560855B (zh) * 2021-03-26 2023-05-23 成都苑东生物制药股份有限公司 环烷基甲酰胺类衍生物、其制备方法及用途
WO2025196447A1 (en) 2024-03-22 2025-09-25 Sitryx Therapeutics Limited Thiadiazoles as glutaminase 1 inhibitors
WO2025196446A1 (en) 2024-03-22 2025-09-25 Sitryx Therapeutics Limited Thiadiazoles as glutaminase 1 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108785305B (zh) * 2011-11-21 2021-10-29 卡利泰拉生物科技公司 谷氨酰胺酶的杂环抑制剂
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
KR20160100407A (ko) 2014-01-06 2016-08-23 리젠 파마슈티컬스 소시에떼 아노님 신규한 글루타미나제의 저해제
GB201409624D0 (en) * 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US9938265B2 (en) * 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US10323028B2 (en) * 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer

Also Published As

Publication number Publication date
US20170333429A1 (en) 2017-11-23
PH12018501133A1 (en) 2019-01-21
MX2018006483A (es) 2019-08-12
CA3005517C (en) 2023-12-12
US10040789B2 (en) 2018-08-07
CA3005517A1 (en) 2017-06-08
PE20181522A1 (es) 2018-09-24
DOP2018000135A (es) 2018-06-30
JP2018535235A (ja) 2018-11-29
MY195680A (en) 2023-02-03
EA035519B9 (ru) 2020-08-10
CL2018001409A1 (es) 2018-12-07
ES2796562T3 (es) 2020-11-27
CO2018006930A2 (es) 2018-10-10
AR106875A1 (es) 2018-02-28
TN2018000118A1 (en) 2019-10-04
SV2018005700A (es) 2019-03-07
TW201731511A (zh) 2017-09-16
CN108349965A (zh) 2018-07-31
SG11201803808VA (en) 2018-06-28
EP3383872B1 (en) 2020-05-20
BR112018008330A2 (pt) 2018-10-30
EA035519B1 (ru) 2020-06-29
EP3383872A1 (en) 2018-10-10
ZA201804361B (en) 2019-07-31
AU2016361834A1 (en) 2018-07-12
DK3383872T3 (da) 2020-06-08
AU2016361834B2 (en) 2019-11-14
WO2017093301A1 (en) 2017-06-08
JP6821680B2 (ja) 2021-01-27
NZ743699A (en) 2023-02-24
EA201891239A1 (ru) 2018-11-30
NI201800063A (es) 2018-10-18
KR20180083411A (ko) 2018-07-20
BR112018008330B1 (pt) 2023-03-07
CN108349965B (zh) 2021-10-26

Similar Documents

Publication Publication Date Title
ZA201904695B (en) Amino-triazolopyridine compounds and their use in treating cancer
SG11202104356VA (en) Bt1718 for use in treating cancer
IL249020A0 (en) 1,3,4-thiadiazole compounds and their use in cancer treatment
ZA201803742B (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
GB201516504D0 (en) Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
ZA201804361B (en) 1,3,4-thiadiazole compounds and their use in treating cancer
IL259510A (en) 1,3,4-thiadiazole compounds and their use in treating cancer
IL258644A (en) 4,3,1-thiadiazole compounds and their use for cancer treatment
ZA201802618B (en) Anti-cd43 antibody and use thereof for cancer treatment
IL261648A (en) Cinnolin-4-amine compounds and their use in treating cancer
IL259358A (en) Bis-pyridazine compounds and their use in treating cancer
IL262143A (en) Improvements in cancer treatment
IL269121A (en) Usl-311 for use in the treatment of cancer
IL255541A (en) Cabazitaxel and its use for treating cancer
GB2578008B (en) 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment
GB201510764D0 (en) bis-Pyridazine compounds and their use in treating cancer
HK1259160A1 (en) Bis-pyridazine compounds and their use in treating cancer
GB201411111D0 (en) bis-Pyridazine compounds and their use in treating cancer
GB2553684B (en) Ethynylxanthines, preparation and use for cancer treatment

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed